Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis
Study context
- Population
- Sepsis patients (SEPSIS-3 criteria), multicenter SepsisDataNet.NRW studyproteomics in 171
- Participants
- 410 patients
- Exposure
- HCMV-seropositive vs HCMV-seronegative sepsis patients
- Outcome
- Mortality
- Follow-up
- 30 days
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
30-day mortality
HCMV-seropositive vs SeronegativeHazard ratio (95% CI)P value
30-day mortality
1.656(1.135–2.417)
P = 0.008Independent of age
1.673(1.131–2.477)
P = 0.010Observational data: associations, not effects.
Further findings
30-day mortality by increased IL-6, HCMV-seropositive cohort (subgroup)
| HR (95% CI) | P value | ||
|---|---|---|---|
| Increased IL-630-day mortality 63% vs. 24% | 3.250 (2.075–5.090) | P < 0.001 | |
| 0.20.5125Hazard ratio (log scale) |
- IL-6 predictive of outcome only in seropositive cohort; no significant differences in serum IL-6 between groups
Procalcitonin and IL-10 (subgroup)
- Predictive of outcome only in HCMV-seropositive patients
Original publication
Human cytomegalovirus seropositivity is associated with reduced patient survival during sepsis. Crit Care. Published 31 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →